Skip to content

The role of 3D laparoscopic rectal surgery: a randomised controlled trial

2D vs. 3D laparoscopic anterior resection: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN59485808
Enrollment
72
Registered
2015-12-16
Start date
2016-01-02
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal adenocarcinoma Cancer Rectal adenocarcinoma

Interventions

Patients will be identified at local colorectal Multi-Disciplinary Team meetings and outpatient clinics. Potentially eligible patients will be approached by GCP (Good Clinical Practice) trained staff

Sponsors

Yeovil District Hospital NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with adenocarcinoma of the rectum (<15cm from anal verge as measured by staging MRI ) 2. Scheduled to undergo elective laparoscopic TME/ partial mesorectal excision surgery with curative intent, with or without neo-adjuvant treatment and with or without defunctioning stoma formation 3. Written informed patient consent

Exclusion criteria

Exclusion criteria: 1. History of inflammatory bowel disease 2. Patients requiring abdomino-perineal excision or surgery without anastomosis 3. Advanced tumours involving adjacent organs (TNM5 T4aNxMx) 4. Surgery performed with palliative intent or under unplanned/emergency settings 5. Previous treatment (radiotherapy/abdominopelvic surgery) for endometrial, ovarian, prostate, bladder (TURBT ok), anal or vaginal cancer 6. Patient or surgeon refusal to enter study or accept randomisation result

Design outcomes

Primary

MeasureTime frame
The total number of technical errors during each operation. Each operation will be digitally recorded and analysed unedited by a blinded assessor using Objective Clinical Human Reliability Analysis (OCHRA)

Secondary

MeasureTime frame
1. Total operating time 2. Operative blood loss 3. Conversion to open surgery 4. Postoperative length of stay 5. 30 day readmission 6. Histological outcomes, including mesorectal specimen quality, which will be assessed by a pathologist using standardised criteria 7. Postoperative complications using the Clavien-Dindo classification 8. 30 day mortality 9. Surgeon-reported feedback on the adverse effects of the imaging system will also be recorded such as blurred vision, altered vision, light headedness and or dizziness 10. Surgeon-reported cognitive load assessment All complications occurring in hospital (index stay or re-admission) will be recorded up to 30 days.

Countries

England, United Kingdom, Wales

Contacts

Public ContactNader Francis

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 7, 2026